Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Schering-Plough |
---|---|
Information provided by: | Schering-Plough |
ClinicalTrials.gov Identifier: | NCT00506545 |
This is a randomized, double-blind, placebo-controlled, crossover, single center study of SCH 619734 in subjects with chronic cough from an unknown cause. Subjects will be randomized to receive SCH 619734 or placebo for 7 days with 7 days' follow-up. After a 6 week washout period, subjects will be crossed over to the other treatment. The primary objective is to evaluate the effectiveness of SCH 619734 in reducing cough reflex sensitivity as determined by a challenge with capsaicin, an agent that induces cough.
Condition | Intervention | Phase |
---|---|---|
Cough |
Drug: SCH 619734 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study |
Official Title: | Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Idiopathic Cough |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | P04888, SCH 619734 |
Study First Received: | July 23, 2007 |
Last Updated: | October 29, 2007 |
ClinicalTrials.gov Identifier: | NCT00506545 |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Signs and Symptoms Respiratory Tract Diseases Respiration Disorders Signs and Symptoms, Respiratory Cough |